After one week, six critically ill patients in Israel survived. Four of them showed improvement in respiratory parameters.
Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the country’s compassionate use program.
Placental #celltherapy as a potential #treatment for #Covid_19: join us at the Cell & Gene Therapy Manufacturing Digital Week of @InformaConnect , for a webcast by Racheli Ofir PhD, VP Research & Intellectual Property at @Pluristem. Wednesday, April 22nd: https://t.co/V00elVahth
— Pluristem (@Pluristem) April 17, 2020
The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.
Read more.